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ABSTRACT  
Objective: Malaria is the deadliest infectious diseases affecting millions of people worldwide. Several strategies have been under extensive research 
since decades including chemoprophylaxis and other disease antimalarial interventions like malaria vaccine. The vaccine development is more 
difficult to predict than drug development and presents a unique challenge as already there has been no vaccine effective against a parasite. For 
development and screening of malaria vaccine, a suitable animal model is the prime requirement. Non-human primate models are considerably a 
good choice to mimic human malarias, but due to various reasons like ethical, cost effective, maintenance and relative ease of conducting 
experiments. Rodent’s malaria vaccination models remain the preferred choice. 
Methods: To develop such model we required 100% lethal host/parasite system that would be an ideal system for experimental vaccination 
studies. Such a rigorous model is particularly required for the identification and development of suitable adjuvant/co-adjuvant(s) for future human 
malaria vaccines.  
Results: Because, P. yoelii nigeriensis invariably causes a 100% lethal fulminating infection in Swiss mice, so in present studies, we vaccinate Swiss 
mice with P. yoelii nigeriensis total P. yoelii nigeriensis - Soluble antigen (Pyn-SA)and saponin as adjuvant, following 100% lethal study homologous 
challenge and then followed by passive transfer of experiment.  
Conclusion: P. yoelii nigeriensis caused a fulminant 100% lethal infection in mice (as saw in the control groups). The protection observed in the 
vaccinated group of mice can be unambiguously ascribed to vaccine-induced protective immunity only.  
Keywords: Malaria, Vaccine, Pre-erythrocytic (PE),Blood-stage (BS), Circumsporozoite protein (CSP), Merozoite surface protein (MSP). 
 
INTRODUCTION 
Malaria is one of the greatest burdens to mankind, with a mortality 
rate that is unrivaled by any other modern disease unlike 
tuberculosis [1]. This incapacitating disease is caused by four 
different agents (Plasmodium falciparum, Plasmodium vivax, 
Plasmodium malariae and Plasmodium ovale) of the same genus [2]. 
Malaria remains one of the leading causes of morbidity and 
mortality in the tropics. Malaria affects more than 2400 million 
people; about 40% of the global population is at a risk of malaria. In 
some countries with a heavy malaria burden, the disease may 
account for as much as 40% of public health expenditure, 30-50% of 
in-patient admissions, and up to 50% of out-patient visits. It has 
been estimated that there were about 207 million cases of malaria in 
2012 and an estimated 627, 000 deaths [3, 4].  
Several strategies have been tested to combat this disease and 
innumerable attempts have been made to launch a malaria vaccine. 
Despite several efforts in the past five decades, we do not have a 
clinically accepted malaria vaccine. Safety, efficacy, cost and 
provision of the vaccine to all communities are major concerns in 
malaria vaccine issue [5,6]. Some of the difficulties encountered in 
malaria vaccine research are, parasite induced immunosuppression, 
intracellular parasites, mutation of parasites, multiple antigens 
(specific to species and stage), antigenic variations, lack of suitable 
animal models for malaria vaccination studies, lack of effective and 
safe adjuvant/co-adjuvant, and that of suitable animal models to 
identify, evaluate and develop them, lack of the availability of in-
vitro assays that can predict protective immunity in-vivo and lack of 
detailed knowledge of the mechanisms of pathogenesis and 
protective immunity in malaria [7]. 
Naturally acquired immunity to malaria is slow to develop, non-
sterilizing and short-lived in the absence of continuous exposure. 
The parasite rapidly develops resistance to anti-malarial drugs and 
treatment is often followed by reinfection. Hence, there is an urgent 
need to develop a malaria vaccine [8]. 
Preclinical vaccination studies have been tried in primate; avians 
and rodent models [9]. Rodent malaria causing parasites provide 
an available model for understanding the mechanisms of human 
Plasmodium infections [10]. Studies involving the mouse model of 
blood stage malaria infections have demonstrated that CD4+
Adjuvants are substances (e. g. Minerals salts, oil emulsions, 
bacterial products, saponins) which upon administration lead to 
non-specific immune stimulation. When the adjuvants is used in a 
vaccine, the goal is to induce immune response and memory 
sufficient to protect against a harmful organism while for the 
production of antibodies the main goal is to elicit the highest 
specific antibody response achievable [14]. The acceptability of 
 Th1 
and Th2 cells are essential for the control of primary parasitemia 
and specific antibodies are responsible for the clearance of 
malaria-causing parasites thereafter. Immunity against severe 
malaria may also depend upon the host's ability to fine tune the 
magnitude and process of the cellular immune response, which 
allows appropriate production and timing of inflammatory or anti-
inflammatory cytokines at key stages of the infection [11,12]. 
Many rodent malaria models have been identified, developed and 
studied. Out of these, the most widely used as experimental 
vaccination models are P. yoelii 17X, P. yoelii (YM strain), and P. 
berghei infection in various types of mice [13]. Using the rodent 
models, a diverse group of adjuvants like saponin, aluminium 
hydroxide, non-ionic block polymers, copolymer P1004, IFN-α, and 
detoxified lipopolysaccharide as well as bacteria including 
Bordetella pertussis, Corynebacterium parvum and Salmonella 
typhimurium have been evaluated [14]. Protective immunity to the 
asexual blood forms of malaria parasites, the pathogenic stage of 
the life cycle, involves both cellular and antibody mediated 
mechanisms [15]. 
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side effects is determined by the species in which the adjuvant is 
applied [16].
With aforementioned background, we had proposed the following 
hypothesis that is to experimentally immunize mice using Pyn-
soluble antigens. In this study, we develop this host/parasite system 
into a rigorous rodent malaria vaccination model to study the new 
dimensions of immune protection.  
  
MATERIALS AND METHODS 
Animals  
Swiss mice (Mus musculus), male, weighing 20–22 g, supplied by the 
Central Animal Facility. NIPER, were used in all the experiments. 
Animals were kept in temperature (22–24°C) and light (12 h on/off) 
controlled rooms and provided with standard animal feed and clean 
water (with 0.005% PABA) ad libitum. All experiments were carried 
out in accordance with the Guidelines for Care and Use of Animals in 
Scientific Research, Indian National Science Academy, New Delhi, 
India, as adopted and promulgated by the Institutional Animal Ethics 
Committee.  
Parasites 
Pyn-MDR has been used for the preparation of vaccine and for 
infecting the mice. The strain has been maintained in Swiss mice by 
serial passage. The strain shows a high level of virulence and 
produces 100% lethal infection. The parasite strain was maintained, 
separately, by serial infected-blood-passage in mice and 
cryopreservation. 
Reagents 
Saponin, used as an adjuvant for the vaccine was from HIMEDIA. 
Histopaque-1077 from Sigma Aldrich. Bio-Rad’s Bradford kit and 
Bradford method were used for estimating the protein content in the 
crude antigen preparation. The reagents used were bovine serum 
albumin (BSA), concentrating dye reagent, Wright’s stain 
(HIMEDIA), ethanol (Sigma Aldrich), isopropyl alcohol, DMEM 
(PAA), disodium hydrogen phosphate (Merck India Ltd., Mumbai, 
India; 9.5 g) and potassium dihydrogen phosphate (Merck; 9.06 g) 
for preparing the staining buffer and 3.2% w/v sodium citrate saline 
solution as the anti-coagulant [17].  
Initiation of infection 
For initiation of infection, mice were infected i.p. with a counted 
inoculums of 1x107
Enumeration of parasitemia 
 infected erythrocytes (IE), obtained by cardiac 
puncture from a previously infected donor mouse. Infection was 
maintained by serial blood passage. 
Brief procedure for the enumeration of parasitemia is as follows. A 
thin blood smear made from a small drop of cut tail-blood of a 
mouse was air-dried. The smear was then covered with Wright’s 
stain. After about 4–5 min it was covered with staining buffer for 12 
min. It was then washed with more staining buffer and air dried. The 
slides were monitored under oil immersion lens of a light 
microscope (Model no. Eclipse E-600, Nikon, Japan). The parasitemia 
was expressed as % IE after microscopic examination of 1 x 104
Preparation of antigen 
 
erythrocytes.  
In most of the vaccination studies, the soluble material, which is a 
small representative subset of the total parasite antigens, was found 
as potent immunogen as the intact IE [18]. Brief procedure of 
antigen preparation is as follows. First, 2 donor mice were prepared 
by injecting with a counted inoculums of 1 x 106
 
 IE. On day 4, the 
mouse with 2–5% parasitemia was used to infect a batch of 15 
healthy mice conditioned with 12 h light-dark cycle.  Briefly [18], 
when donor mice had > 80 % parasitemia, the maximum number of 
schizonts, they were bled in pre-chilled citrate saline. The blood-
citrate mixture was then kept overnight at 4°C which results in the 
formation of different layers and infected erythrocytes and normal 
erythrocytes layers become visible. Upper infected erythrocytes 
layer (schizonts rich layer) was aspirated using a sterile Pasteur 
pipette in a sterile centrifuge tube and centrifuged at 3000 g for 15 
min at 4°C. They were washed thrice with chilled DMEM. Smear 
slides were prepared and parasitemia was checked. When 90% 
schizonts and very few rings were seen, the pelleted IEs were lysed 
by the rapid cycle of freezing and thawing. Figure 1 clearly shows 
the lysis of IEs (arrow marked). The crude cell lysate was 
centrifuged, and clear supernatant was decanted. Protein estimation 
for this supernatant was done using the Bradford method (Biorad 
Protein Estimation Kit) and its concentration was adjusted to 2.1 
mg/ml. The antigen-based vaccine was stored as aliquots of 100 µl at -
70°C. The same antigen preparation was used in all the experiments. And 
similarly NEA was prepared using blood of normal mice. 
 
Fig. 1: Cell lysis showing ruptured RBCs 
 
Protein estimation 
The Bio-Rad Protein Assay, based on the method of Bradford, is a 
simple and accurate procedure for determining concentration of 
solubilized protein. It involves the addition of an acidic dye to protein 
solution, and subsequent measurement at 595 nm with 
spectrophotometer or microplate reader. Comparison to a standard 
curve provides a relative measurement of protein concentration [19]. 
Vaccine formulation 
After preparation of antigens, vaccine is prepared by mixing antigen 
and adjuvant using double locking hub connector. Mixing was done 
at 4°C in sterile conditions at the time of dosing or immunization. 
For this antigens is taken in one syringe and adjuvant in another 
syringe and by the help of piston two were mixed thoroughly until 
an emulsion is formed [20]. 
Immunization and challenge 
The antigen aliquots were prepared into solutions along with 
saponin as the adjuvant in the same concentration as the antigen. 
The mixing was done at 4°C. The doses were then administered s. c. 
or i. p., on days 0, 15 and 30. The immunized mice were then 
challenged on day 45 with inoculums of 1 x 103
Preparation of the immunized mouse serum  
 IE, consisting mainly 
of ring stage of the plasmodial parasite. The course of infection, 
leukocyte counts and splenic parameters was observed post 
challenge. The protection was assessed in terms of (i) duration of pre-
patent period, (ii) % peak parasitemia, (iii) duration of the patent period, 
and outcome of challenge in terms of mortality (% survival) [20]. 
Blood from mice (immunized) was collected without anticoagulant 
in a sterile glass syringe by cardiac puncture, and was transferred to 
a sterile centrifuge tube that was kept vertical. While transferring 
the blood from a syringe to a tube, care was taken to avoid any 
haemolysis. The blood was allowed to clot by allowing the tube to 
stand at 37°C for not more than 1 h.  
After 30 min, the clot was detached from the walls of the tube with 
the help of a sterile pasteur pipette. The tube was then kept at 4°C 
for the contraction of the clot. After keeping it overnight, the serum 
was separated by centrifugation (10,000 g, 10 min, and 4°C). The 
clear supernatant (serum) was aseptically transferred into a sterile tube. 
All the sera were stored in sterile conditions at -20°C until use. Similarly 
normal mouse serum was prepared from normal mice. Serum was thus 
obtained from immunized mouse is known as HIS [20]. 
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Passive transfer of protection by HIS 
2 Groups of mice (3/group) were injected with 0.2 ml of HIS/mouse 
on days -2,–1, 0, +1, +2, +3, +4, +5, +6, and +7 relative to the day of 
parasite challenge (day 0), i. P. The control group was injected with 
0.2 ml normal mouse serum (NMS)/mouse, similarly. All the mice in 
each group were challenged with 1x103
Splenectomy 
 homologous IE (rings), i.p, 
on day 0, and assessed for protection as described [20].  
During the erythrocytic stages of malaria infection, the spleen is the 
main organ involved in the development of the immune response 
and in elimination of pRBC [21]. The mice were anaesthetized and 
then sacrificed humanely by cervical dislocation. The concerned area 
was wiped clean using isopropyl alcohol and cut open using 
sterilized pair of sharp scissors. The spleen was excised and its size 
and weight were determined to show the difference between 
immunized, normal mice and infected mice. Also dab smear of 
spleen of immunized, normal and Pyn infected mice were made and 
compared with each other (Fig. 2). 
 
 
Fig. 2: Comparison of dab smears of spleen of (A) Infected mice 
(B) Immunized mice 
 
Statistical analysis  
Values are expressed as mean ± S. E. M. in percentage was calculated 
as: 100-[(mean % parasitemia treated/ control) X 100]. For 
comparison of mean of different groups one way ANOVA and 
Student’s t- test was used. All the statistical calculations were made 
on the Sigma Stat 3.5. A value of p < 0.05 was considered significant. 
RESULTS 
Study of the course of infection of Pyn –MDR strain in mouse 
model 
Pyn-MDR is a highly virulent strain causing 100% fatality in Swiss 
mice. The course of infection was studied by infecting i. p. in a group 
of mice (n=5), with inoculums of 1 x 106
 
 IE respectively (Fig. 3). The 
percent parasitemia rose from day 2 to day 8. Mice became patent 
on day 2 and displayed a maximum parasitemia of 69.56 ± 2.22% on 
day +8. All mice succumbed to the fulminating infection by day +9.  
Fig. 3: Courses of infection of P. yoelii nigeriensis in Swiss mice, 
when inoculums sizes of 1 x 106
 
 IE (n = 5) were given i. p. 
Parasitaemia is expressed as mean ± S. E. M. 
Immunization  
This was a pilot study to determine the immunizing efficacy of the 
whole antigen vaccine. Five different groups were made – vehicle 
control, vehicle + saponin (50 μg), vehicle + NEA (50 μg), vehicle + 
Pyn-SA (50 μg), and vehicle + Pyn-SA (50 μg) + saponin (50 μg). 
These groups were given the mentioned doses on day 0, 15 and 30. 
On day 45, all the groups were challenged with inoculums of 1 x 103
 
 
IE. All the mice in the vehicle control group perished on day 16, with 
a mean parasitemia of 81.43 ± 2.75% at the time of death. The 
parameters observed were, % parasitemia and pre-patent period. 
The peak parasitemia reached was around 41% in the immunized 
group on day +11 (Fig. 4 (a), 4(b)). The survival in this group was 
also significantly increased (Table 1). While all mice in other groups 
perished, 4 out of 6 mice, survived in the immunized group. The MST 
of this batch was over 2 months. The mice were now completely 
immune to the infection and showed no parasitemia in the blood 
smears.  






saponin(50 ug)  
Vehicle + NEA (50 
ug)  
Vehicle + Pyn-SA 
(50 ug)  
Vehicle + Pyn-SA (50 ug) + 
saponin (50 ug)  
3  1.3 ± 0.018  1.5 ± 0.364  0.106 ± 0.001  0.25 ± 0.015  0  
4  3.5 ± 0.09  4.5 ± 0.9  1.06 ± 0.09  2 ± 0.18  1.3 ± 0.23  
5  6.3 ± 0.7  10.77 ± 0.746  4.135 ± 0.32  4.3 ± 0.22  2.24 ± 0.19  
6  12.83 ± 1.72  17.34 ± 0.944  9.401 ± 0.34  7.58 ± 0.28  4.5 ± 0.4  
7  20.85 ± 1.82*  41.605 ± 0.714  18.94 ± 2.13*  10.42 ± 0.4  7.7 ± 0.39  
8  40.5 ± 2.1*  59.8 ± 2.15*  33.65 ± 2.22*  16.08 ± 0.26  11.42 ± 0.23  
9  65 ± 1.2  75.08 ± 1.31  41.12 ± 1.73*  25.02 ± 0.47  21.175 ± 0.4  
10  75.98 ± 1.58  81.33 ± 0.73  47.38 ± 1.4  30.445 ± 0.57  32.951 ± 0.36  
11  81.43 ± 2.75*  D  51.165 ± 2.07  41.26 ± 2.5*  41.64 ± 2.33*  
12  D  D  68.11 ± 2.14*  45.93 ± 1.41  30.008 ± 1.68*  
13  D  D  D  50.314 ± 3.19**  28.02 ± 1.019  
14  D  D  D  58.34 ± 3.01  24.678 ± 0.27  
15  D  D  D  69.48 ± 2.73  20.114 ± 0.16  
16  D  D  D  78.44 ± 2.79*  18.812 ± 0.15  
17  D  D  D  D  15.03 ± 0.37  
18  D  D  D  D  13.178 ± 0.36  
19  D  D  D  D  10.23 ± 0.11  
20  D  D  D  D  7.06 ± 0.15  
21  D  D  D  D  5.3 ± 0.23  
22  D  D  D  D  4.1 ± 0.11  
23  D  D  D  D  2.3 ± 0.025  
24  D  D  D  D  1.1 ± 0.013  
25  D  D  D  D  0  




Fig 4: (a) Challenge results of mice vaccinated with saponin as 
an adjuvant. Mice (6/experimental group; 6/control groups) 
were vaccinated, s. c. and i. v. by administering/mouse a. DMEM 
(0.5 ml as vehicle), b. saponin (50 μg), c. NEA (50 μg), d. Pyn-SA 
(50 μg), e. vaccine (Pyn-SA + saponin; 50 μg each), on days 0, 15 
and 30. All the mice in each group were randomly challenged, i. 
p., with 1x103
 
 IE/mouse on day 45 after first vaccine shot (day 0 
in figure). Percent parasitemia was determined daily by 
microscopic examination of the Wright’s stained thin tail-blood 
films. The data are mean ± SD, n = number of mice. (b) 
Comparison of pre-patent periods of different groups of 
immunization 
Passive transfer of immune protection by HIS  
Mice, which received 0.2 ml of NMS, became patent on day +5, 
developed a fulminating infection on day +15 and died on day +16. 
Whereas mice which received 0.2 ml HIS, became patent on day +6, 
developed a fulminating infection of 34.5±6.35 on day +16, in which 
1 of them, gradually sub-sided by day +17, and resulted in 60% 
protection. The parameters observed were, % parasitemia and pre-
patent period (Fig. 5 (a), 5(b) (Table 2). Isodiagnostic tests, run 
individually on the surviving mice, on day +28, confirmed the 
complete elimination of circulating parasites. 
 
Table 2: Passive transfer of immune protection by HIS 
Days (post 
infection)  
Control group  Experimental 
group  
3  0  0  
4  0  0  
5  0.903 ± 0.038  0  
6  5.916 ± 0.3  0.815 ± 0.001  
7  10.5 ± 0.58  4.031 ± 0.02  
8  16.5 ± 1.9  8.42 ± 0.05  
9  19.46 ± 2.34*  12.15 ± 1.45  
10  25.6 ± 4.56*  14.12 ± 2.13  
11  35.256 ± 6.78** 
(n=2)  
16.33 ± 4.14*  
12  38.16 ± 7.77**  19.415 ± 4.3*  
13  12.47 ± 0.32  21.11 ± 5.11*  
14  5.68 ± 0.18  25.295 ± 5.9**  
15  2.2 ± 0.44 (n=0)  30.15 ± 6.05**  
16  D  34.5 ± 6.35***  
17  D  21.90 ± 3.22 (n=2)  
18  D  14.2 ± 1.45  
19  D  9.7 ± 0.6  
20  D  5.5 ± 0.25  
21  D  2.81 ± 0.33  
22  D  0  
 
Fig. 5: (a) Passive transfer of protection against P. yoelii 
nigeriensis in mice which received HIS - 2 Groups of 3 mice each 
were injected i. p., with, 0.2 ml of HIS/mouse on days -2,-1, 0, 
+1,+2, +3,+4, +5,+6, +7,+8 and +9 relative to the day of parasite 
challenge (day 0). The control group of mice were injected, 0.2 
ml/mouse of NMS, similarly (b) Comparison of pre-patent 
periods of different group during passive transfer of infection. 
 
Determination of Splenic parameters 
When mice are completely immune to infection then there spleen 
were removed, its size, weight and shape were determined (Fig. 6) 
(Table 3). There is the clear difference between spleen of 
immunized, normal and infected mice spleen. As malaria parasite 
destroys RBCs that are usually removed from circulation by spleen 
therefore weight of the spleen is expected to be increased in 
plasmodium infected mice but in case of malaria immunized mice 
parasitemia was decreased so the size of the spleen comparable to 
size of normal mice spleen.  
 
Table 3: Splenic parameters of different groups 






Normal mice  25.5 ± 2  0.118 ± 0.8  1.7  
Immunized mice  25 ± 2  0.14 ± 0.004  1.9  
Pyn-MDR infected 
mice  
22.5 ± 0.5  0.2 ± 0.004  2.3  
 
 
Fig. 6: Comparison of Spleen size in A) Normal mice, B) Pyn-SA 
immunized mice and C) Pyn-MDR infected mice 
 
DISCUSSION  
In the present studies, a new rigorous rodent malaria vaccination 
model has been successfully developed by using Pyn-SA, and 
saponin as an adjuvant. Because at present apparently no robust 
rodent malaria vaccination model is available for the evaluation of 
new potential adjuvants, this model may now be very useful in the 
evaluation of new potential synthetic and or natural products-
derived adjuvants. It is clear that widespread and increasing 
resistance of malaria parasites to antimalarial drugs, vaccination 
against malaria is the only cost-effective and implementable strategy 
to control malaria [22]. Several studies have demonstrated that Ig 
purified from the sera of immune adults living in endemic regions, 
and experimentally immunized animals can passively transfer 
protection against live challenge [23].  
Animal studies of malaria vaccination clearly demonstrate the potential 
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using different Plasmodial component e. g. immunization with P. 
knowlesi Mz can induce immunity which has been found to be superior 
than the immunity development from natural infection [24]. In this study 
the host parasites system, Pyn infection in mice has been utilized. Pyn is 
known to cause a very severe, fulminating infection in mice which 
invariably results in their death due to heavy infection. In this study 
rodent malaria vaccination models have been developed using Pyn-SA 
and saponin as adjuvant, in order to study new dimensions of immune 
response. The rodent malaria parasites Pyn produces generally self-
limiting infection in laboratory mice and this experimental model 
has been used in a number of recent studied of acquired immunity to 
malaria [25]. 
ABBREVIATIONS  
The development of immunity to Pyn has been shown 
to be T cell dependent and B cell dependent [26]. Passive transfer 
experiments have shown that a protective humoral factor, 
presumably antibody, is present in the serum of recovered mice [27] 
while other work has indicated that antibody independent cell- 
mediated immune response mechanisms may play a role in the 
acquisition and maintenance of immunity to Pyn [27].  In the general 
lethal malaria infections to reinfection caused by Pyn in mice and by P. 
falciparum in naïve children, it is not clear what constitutes a protective 
immune response in patients who survive primary infections without 
any experimental or therapeutic intervention [28]. While a large body of 
literature exists on the role of acquired immune response in immunity 
against malaria relatively little is known about the native or early 
immune mechanisms effective against a potentially lethal primary 
malaria infection [29]. Furthermore it takes many years for natural 
immunity to develop, and the immunity is not only species but also stage 
specific. Although immunity to malaria is complex and not properly 
understood, a number of different immune effectors’ mechanisms are 
well described including CD8+ T cells (liver stage) and both antibody and 
CD4+ T cells to the blood stage [30]. In the recent years the antigen 
specificity of some of these immunological processes has been defined 
and selected antigenic targets are now being incorporated into putative 
vaccines. How these antigens are delivered how their immunogenicity is 
enhanced and how and with what other antigens they are combined will 
largely determines the speed at which effective malaria vaccine for 
humans are developed [31]. 
CONCLUSION 
A 100% lethal host/parasite system would be an ideal system for 
experimental vaccination studies. Wherein the protection results 
can be expected to be free-from infection-induced immunity and 
other host-related factors. Pyn invariably caused a fulminant 100% 
lethal infection in mice (as seen in the control groups). The 
protection observed in the vaccinated group of mice can be 
unambiguously ascribed to vaccine-induced protective immunity 
only [20]. Therefore, it was concluded that Pyn/Swiss mice model can 
be very useful for screening of potential new adjuvants/co-adjuvants. 
The results of this study clearly demonstrate that vaccination of Swiss 
mice with Pyn total parasite soluble antigen (Pyn-SA) and saponin, 
following 100% lethal homologous challenge, has often resulted in 60% 
protection. So far the mechanisms of protective immunity concerned 
which is not completely understood, it is believed that, both humoral and 
cellular mechanisms provide immune protection. 
DMEM- Dulbecco’s modified eagle’s medium, HIS- Hyper immune 
serum, IE- Infected erythrocytes, MDR- Multi drug resistant, NEA-
Normal erythrocyte antigen, NL - Non lethal, NMS-Normal mouse 
serum, NF-kB-Nuclear factor, NK cells- Natural killer cells, pRBC-
Parasitized red blood cells, Pyn-P. yoelii nigeriensis, Pyn-SA-P. yoelii 
nigeriensis soluble antigen, QS-Quillaja saponaria. 
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